A method for preparing Neoechinulin B in gram quantities
Neoechinulin B was successfully prepared by using a simplified synthetic route and tryptophan ester hydrochloride as the starting material through acylation, isopentenylation, oxidative dehydrogenation, hydrolysis, amino acid condensation and cyclization dehydration steps. This solved the problems of long synthetic routes, low yields and harsh conditions in the existing technology, and achieved the goal of gram-scale preparation and green chemistry.
Patent Information
- Application Number
- CN202611605952.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-10-16
- Publication Date
- 2026-11-17
AI Technical Summary
Existing chemical synthesis methods for Neoechinulin B suffer from problems such as lengthy synthetic routes, low overall yield, harsh conditions, and difficulty in scale-up, and do not conform to the trend of green chemistry.
Neoechinulin B was prepared by constructing an indolepiperazine dione skeleton through steps including acylation, isopentenylation, oxidative dehydrogenation, hydrolysis, amino acid condensation, deprotection, and cyclization dehydration, using tryptophan ester hydrochloride as the starting material.
A simplified synthetic route was achieved, the overall yield was improved, it is suitable for gram-scale preparation, and the use of strong bases, high temperatures and heavy metal reagents was avoided, which meets the requirements of green chemistry.
Smart Images

Figure CN123106635A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of organic synthesis technology, and in particular to a method for preparing Neoechinulin B at gram scale. Background Technology
[0002] Indole alkaloids are among the most abundant secondary metabolites in nature, widely distributed in plants and fungi, and are an important resource of drug lead compounds. Piperazinide diones are the smallest cyclic peptide structural units, often embedded within complex natural product skeletons; while indole-piperazinide diones (IDAs), as an important class of cyclic dipeptides, are a common and important family of secondary metabolites in fungi, with most compounds isolated from different species of the Penicillium genus. Penicillium ) and Aspergillus ( Aspergillus ( ), usually have a variety of biological activities.
[0003] Neoechinulin B is derived from marine fungi. Aspergillus A novel indopiperazine dione alkaloid with a complex skeleton, containing a piperazine dione skeleton, indole ring, and isopentenyl unit, has been isolated from [a specific organism / organism], showing potential value in drug development. However, as a secondary metabolite of marine fungi, Neoechinulin B is found in extremely low amounts in natural sources. Direct isolation and extraction from fungi not only results in low yields but also is limited by the availability of natural resources, severely hindering its subsequent development and utilization.
[0004] Chemical synthesis is the main route for obtaining these compounds. However, existing synthetic methods generally have the following drawbacks: First, the synthetic routes are lengthy and involve many steps, resulting in significant cumulative losses at each step and a low overall yield; second, the conditions for key reaction steps are relatively harsh, the regioselectivity is slightly poor, there are many side reactions, and the yield is unstable; third, some methods still rely on strong bases, high temperatures, or heavy metal reagents, making it difficult to achieve gram-level or higher production and not in line with the trend of green chemistry.
[0005] Therefore, developing a synthetic method for Neoechinulin B that is simple in its synthetic route, uses readily available raw materials, operates under mild conditions, has stable yields, and is suitable for gram-scale preparation has become an urgent technical problem to be solved in this field. Summary of the Invention
[0006] The purpose of this invention is to address the problems existing in the prior art by providing a gram-scale preparation method for Neoechinulin B. Starting with tryptophan ester hydrochloride, the method involves sequentially undergoing phthalic anhydride acylation, isopentenyl-9-BBN regioselective isopentenylation, oxidative dehydrogenation of 2,3-dichloro-5,6-dicyanobenzoquinone, lithium chloride hydrolysis, amino acid condensation mediated by 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and 1-hydroxybenzotriazole, hydrazine hydrate deprotection, acetic acid cyclization, and cyclization and dehydration reactions of 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and cuprous chloride to construct the indolepiperazine dione skeleton. This solves the problems of lengthy synthetic routes, low overall yields, harsh conditions, and difficulty in gram-scale scaling-up in the prior art.
[0007] To achieve the above objectives, the present invention provides a gram-scale preparation method for Neoechinulin B, comprising the following steps: S1. Tryptophan ester hydrochloride is acylated with phthalic anhydride, and then isopentenyl-9-BBN is added to carry out isopentenylation to obtain the first intermediate product. S2. The first intermediate product is subjected to an oxidative dehydrogenation reaction with 2,3-dichloro-5,6-dicyanobenzoquinone to obtain the second intermediate product; S3. After hydrolyzing the second intermediate with lithium chloride, serine methyl ester hydrochloride, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and 1-hydroxybenzotriazole are added to carry out an amino acid condensation reaction to obtain the third intermediate. S4. The third intermediate product is deprotected with hydrazine hydrate, and then acetic acid is added to carry out a cyclization reaction to obtain the fourth intermediate product. S5. The fourth intermediate, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, was subjected to a cyclization and dehydration reaction with cuprous chloride to obtain Neoechinulin B.
[0008] In some alternative embodiments, the structural formulas of tryptophan ester hydrochloride, the first intermediate, the second intermediate, the third intermediate, and the fourth intermediate are shown in formulas (1)-(5): R are each independently selected from methyl, ethyl, tert-butyl, or phenyl; the structural formula of Neoechinulin B is: .
[0009] In some optional embodiments, in S1, the specific steps of the acylation reaction include: dissolving tryptophan ester hydrochloride, phthalic anhydride and triethylamine in toluene, and refluxing and stirring at 80-150°C for 9-25 h to obtain an acylation intermediate; the tryptophan ester hydrochloride is selected from at least one of D-tryptophan methyl ester hydrochloride and L-tryptophan methyl ester hydrochloride.
[0010] In some optional embodiments, S1, after the acylation reaction is completed, further includes: quenching the reaction mixture with a saturated ammonium chloride solution, extracting the aqueous layer with ethyl acetate 2-4 times, washing the combined organic layer with a saturated sodium chloride solution, drying with anhydrous sodium sulfate, filtering, and concentrating under reduced pressure.
[0011] In some optional embodiments, in S1, the specific steps of the isopentenylation reaction include: dissolving the acylation intermediate and triethylamine in tetrahydrofuran under an inert gas protection, then adding tert-butyl hypochlorite, followed by dropwise addition of a tetrahydrofuran solution containing isopentenyl-9-BBN; the isopentenylation reaction is carried out at a temperature of -78 to 45°C for 2 to 7 hours; the molar ratio of tryptophan ester hydrochloride, phthalic anhydride, triethylamine, tert-butyl hypochlorite and isopentenyl-9-BBN is 1:(0.5-3.5):(1-5):(1-3.5):(1-6); the ratio of the amount of tryptophan ester hydrochloride, the volume of toluene and the volume of tetrahydrofuran is 1 mmol:(1-40) mL:(1-40) mL; the inert gas is selected from at least one of nitrogen and argon.
[0012] In some optional embodiments, S1, after the isopentenylation reaction is completed, further includes: quenching the reaction mixture with saturated sodium bicarbonate solution, extracting the aqueous layer with ethyl acetate 2-4 times, washing the combined organic layer with saturated sodium chloride solution, drying with anhydrous sodium sulfate, filtering, concentrating under reduced pressure, and separating and purifying by recrystallization.
[0013] In some optional embodiments, the specific steps of the oxidative dehydrogenation reaction in S2 include: dissolving the first intermediate product and 2,3-dichloro-5,6-dicyanobenzoquinone in toluene and stirring at 70-120°C for 2-6 h; the molar ratio of the first intermediate product to 2,3-dichloro-5,6-dicyanobenzoquinone is 1:(1-7); and the molar ratio of the first intermediate product to the volume of toluene is 1 mmol:(3-80) mL.
[0014] In some optional embodiments, S2, after the oxidative dehydrogenation reaction is completed, further includes: quenching the reaction mixture with a saturated sodium bicarbonate solution, extracting the aqueous layer with ethyl acetate 2-4 times, washing the combined organic layer with a saturated sodium chloride solution, drying with anhydrous sodium sulfate, filtering, concentrating under reduced pressure, and separating and purifying by recrystallization.
[0015] In some optional embodiments, in S3, the specific steps of the hydrolysis reaction include: dissolving the second intermediate product and lithium chloride in N,N-dimethylformamide, stirring at 120-200°C for 2-15 h to obtain the hydrolysis product; the specific steps of the amino acid condensation reaction include: mixing and stirring the hydrolysis product with an acetonitrile solution containing serine methyl ester hydrochloride, followed by adding 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, 1-hydroxybenzotriazole and N,N-dimethylformamide; the temperature of the amino acid condensation reaction is 0-40°C, and the time is 12-24 h.
[0016] In some optional embodiments, in S3, the molar ratio of the second intermediate, lithium chloride, serine methyl ester hydrochloride, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, and 1-hydroxybenzotriazole is 1:(1-20):(1-5):(1-3):(1-3); the molar ratio of the second intermediate, the volume of N,N-dimethylformamide, and the volume of acetonitrile is 1 mmol:(0.5-70) mL:(3-70) mL; and the serine methyl ester hydrochloride is selected from at least one of D-serine methyl ester hydrochloride and L-serine methyl ester hydrochloride.
[0017] In some optional embodiments, S3, after the hydrolysis reaction is completed, further includes: cooling the reaction solution to room temperature, concentrating under reduced pressure to remove the solvent, then adding 1 mol / L hydrochloric acid solution to acidify the reaction mixture, extracting the aqueous layer with ethyl acetate 2-4 times, then washing the combined organic layer with saturated sodium chloride solution, drying with anhydrous sodium sulfate, filtering, and concentrating under reduced pressure; after the amino acid condensation reaction is completed, further includes: quenching the reaction with 1 mol / L hydrochloric acid solution, extracting the aqueous layer with ethyl acetate 2-4 times, then washing with saturated sodium bicarbonate solution and saturated sodium chloride solution 1-2 times each, then drying the organic phase with anhydrous sodium sulfate, filtering, concentrating under reduced pressure, and separating and purifying by silica gel column chromatography; the eluent in the silica gel column includes petroleum ether and ethyl acetate in a volume ratio of 2:1.
[0018] In some optional embodiments, in S4, the specific steps of the deprotection reaction include: dissolving the third intermediate in isopropanol, then adding hydrazine hydrate, and stirring at 0-40°C for 1-3 h to obtain the crude product; the specific steps of the cyclization reaction include: dissolving the crude product in a mixed solution of ethanol and toluene, adding acetic acid dropwise, and stirring at 80-150°C for 3-12 h.
[0019] In some optional embodiments, in S4, the molar ratio of the third intermediate, hydrazine hydrate and acetic acid is 1:(1-10):(5-15); the ratio of the amount of the third intermediate, the volume of isopropanol, the volume of toluene and the volume of ethanol is 1 mmol:(4-50) mL:(4-50) mL:(4-50) mL.
[0020] In some optional embodiments, S4, after the deprotection reaction is completed, further includes: quenching the reaction mixture with saturated ammonium chloride solution and extracting the aqueous layer with ethyl acetate 2-4 times; then washing the combined organic layer with saturated sodium chloride solution, drying with anhydrous sodium sulfate, filtering, and concentrating under reduced pressure; after the cyclization reaction is completed, further includes: quenching the reaction mixture with saturated sodium bicarbonate solution and extracting the aqueous layer with ethyl acetate 2-4 times; then washing the combined organic layer with saturated sodium chloride solution, drying with anhydrous sodium sulfate, filtering, and concentrating under reduced pressure.
[0021] In some optional embodiments, in S5, the specific steps of the cyclization dehydration reaction include: dissolving the fourth intermediate, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and cuprous chloride in dichloromethane and stirring at 0-40°C for 5-24 h; the molar ratio of the fourth intermediate, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and cuprous chloride is 1:(0.5-3):(0.01-1); the molar ratio of the fourth intermediate to the volume of dichloromethane is 1 mmol:(4-50) mL.
[0022] In some optional embodiments, S5, after the cyclization dehydration reaction is completed, further includes: quenching the reaction mixture with a saturated sodium chloride solution and extracting the aqueous layer with dichloromethane 2-4 times; then washing the combined organic layer with a saturated sodium chloride solution, drying with anhydrous sodium sulfate, filtering, concentrating under reduced pressure, and separating and purifying by recrystallization.
[0023] Compared with the prior art, the present invention has the following beneficial effects: This invention uses readily available tryptophan ester hydrochloride as a starting material to prepare Neoechinulin B through steps such as acylation, isopentenylation, oxidative dehydrogenation, hydrolysis, amino acid condensation, deprotection, cyclization, and cyclization dehydration. It does not rely on the extraction and separation of natural products, the synthetic route is relatively simple, the key steps have good yields and the side reactions are controllable, and it can realize the gram-scale preparation of Neoechinulin B, providing favorable conditions for its subsequent research and scale-up development. Attached Figure Description
[0024] Figure 1 This is the proton spectrum of the first intermediate product obtained in an embodiment of the present invention; Figure 2 This is the proton spectrum of the third intermediate product obtained in an embodiment of the present invention; Figure 3 This is the proton spectrum of Neoechinulin B obtained in an embodiment of the present invention. Detailed Implementation
[0025] The following embodiments are provided to better understand the present invention and are not limited to the described embodiments. They do not constitute a limitation on the content and scope of protection of the present invention. Any product that is the same as or similar to the present invention, derived by any person under the guidance of the present invention or by combining the features of the present invention with other prior art, falls within the protection scope of the present invention.
[0026] For experiments not specifically described in the examples, the procedures or conditions should be followed according to the conventional experimental procedures described in the literature in this field. Reagents or instruments whose manufacturers are not specified are all commercially available products.
[0027] Example This embodiment provides a gram-scale preparation method for Neoechinulin B, including the following steps: (1) Preparation of the first intermediate product The synthetic route for the first intermediate is shown in the following equation: .
[0028] The specific synthesis method is as follows: 15.9 g of L-tryptophan methyl ester hydrochloride (1a), phthalic anhydride, and an organic base were dissolved in toluene and refluxed at 110 °C for 18 h to carry out the acylation reaction. After the reaction, the reaction mixture was quenched with saturated ammonium chloride solution, and the aqueous layer was extracted three times with ethyl acetate. Then, the combined organic layers were washed with saturated sodium chloride solution, dried with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the acylated intermediate, which could be directly subjected to the isopentenylation reaction without purification. Under argon protection, the acylated intermediate and triethylamine were dissolved in tetrahydrofuran, and then tert-butyl hypochlorite was added. Subsequently, a tetrahydrofuran solution containing isopentenyl-9-BBN was added dropwise. After the addition was completed, the reaction was carried out at -78 °C for 2 h. After the reaction, the reaction mixture was quenched with saturated sodium bicarbonate solution, and the aqueous layer was extracted three times with ethyl acetate. Then, the combined organic layers were washed with saturated sodium chloride solution, dried with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. 17.91 g of the first intermediate (2a) was obtained by recrystallization and purification. The molar ratio of L-tryptophan methyl ester hydrochloride, phthalic anhydride, triethylamine, tert-butyl hypochlorite, and isopentenyl 9-BBN is 1:2:3:2.5:3.5; the molar ratio of L-tryptophan methyl ester hydrochloride, the volume of toluene, and the volume of tetrahydrofuran is 1 mmol:15 mL:15 mL.
[0029] The yield of the first intermediate product was calculated to be 74%.
[0030] The first intermediate was characterized by nuclear magnetic resonance (NMR), and its proton NMR spectrum was obtained, as shown below. Figure 1 As shown. Specific data is as follows: 1H NMR (600 MHz, DMSO) δ: 10.57 (s, 1H), 7.72 (s, 4H), 7.23 (d, J= 8.0 Hz, 1H), 7.16(d, J = 8.0 Hz, 1H), 6.86(t, J = 7.3 Hz, 1H), 6.66 (t, J =7.3 Hz, 1H), 6.24 (dd, J = 17.5 Hz, 10.56 Hz, 1H), 5.11-5.06 (m, 2H), 5.06(d, J = 10.6 Hz, 1H), 3.76-3.71 (m, 1H), 3.70 (s, 1H), 3.52-3.45 (m, 1H),1.55 (s, 3H), 1.47 (s, 1H). 13C NMR (150 MHz, CDCl3) δ:169.7, 167.8, 146.0,140.3, 134.1, 133.9, 131.9, 129.8, 123.3, 121.2, 119.2, 117.8, 112.1, 110.4,106.3, 53.6, 52.8, 39.3, 27.8, 27.6, 24.5.
[0031] (2) Preparation of the second intermediate product The synthetic route for the second intermediate is shown in the following equation: .
[0032] The specific synthesis method is as follows: 7.62 g of the first intermediate (2a) and 2,3-dichloro-5,6-dicyanobenzoquinone were dissolved in toluene and stirred at 100 °C for 3.5 h for oxidative dehydrogenation reaction. After the reaction was completed, the reaction mixture was quenched with saturated sodium bicarbonate solution, and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were then washed with saturated sodium chloride solution, dried with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The second intermediate (3a) was obtained by recrystallization and purification. The molar ratio of the first intermediate to 2,3-dichloro-5,6-dicyanobenzoquinone was 1:4; the molar ratio of the first intermediate to the volume of toluene was 1 mmol: 7 mL.
[0033] The yield of the second intermediate product was calculated to be 74%.
[0034] The second intermediate was characterized by nuclear magnetic resonance (NMR), and its proton NMR spectrum was obtained. Specific data are as follows: 1H NMR (600 MHz, DMSO) δ: 11.46 (s, 1H), 8.41 (s, 1H), 7.86 (s, 4H), 7.39 (d, J = 8.0 Hz, 1H), 6.95-6.90 (m, 2H), 6.69 (t, J = 7.4 Hz, 1H), 6.25 (dd, J= 17.6 Hz, 10.4 Hz, 1H), 5.25-5.21 (m, 2H), 3.79 (s, 3H), 1.64 (s, 6H). 13CNMR (150 MHz, DMSO) δ: 166.2, 164.0, 148.1, 144.6, 137.2, 135.1, 135.0,131.0, 125.0, 123.4, 121.3, 120.0, 118.2, 114.7, 112.3, 112.1, 105.1, 52.4,27.8.
[0035] (3) Preparation of the third intermediate product The synthetic route for the third intermediate is shown in the following formula: .
[0036] The specific synthesis method is as follows: 3.32 g of the second intermediate (3a) and lithium chloride were dissolved in N,N-dimethylformamide and hydrolyzed at 160 °C for 10 h. After the hydrolysis reaction was completed, the reaction solution was cooled to room temperature and concentrated under reduced pressure to remove the solvent. Then, 1 mol / L hydrochloric acid solution was added to acidify the reaction mixture, and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were then washed with saturated sodium chloride solution, dried with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the hydrolysis product. The hydrolysis product was mixed with acetonitrile containing L-serine methyl ester hydrochloride and stirred. Then, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, 1-hydroxybenzotriazole, and N,N-dimethylformamide were added. After the addition was complete, the mixture was stirred at 25 °C for 12 h to carry out an amino acid condensation reaction. After the amino acid condensation reaction was completed, the reaction was quenched with 1 mol / L hydrochloric acid solution, and the aqueous layer was extracted three times with ethyl acetate. The mixture was then washed once with saturated sodium bicarbonate solution and once with saturated sodium chloride solution, followed by drying the organic phase with anhydrous sodium sulfate, filtration, and concentration under reduced pressure. Separation and purification by silica gel column chromatography yielded 2.82 g of the third intermediate (4a). The molar ratio of the second intermediate, lithium chloride, L-serine methyl ester hydrochloride, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, and 1-hydroxybenzotriazole was 1:10:2.5:2:2; the molar ratio of the second intermediate, the volume of N,N-dimethylformamide, and the volume of acetonitrile was 1 mmol:70 mL:70 mL.
[0037] The yield of the third intermediate product was calculated to be 70%.
[0038] The third intermediate was characterized by nuclear magnetic resonance (NMR), and its proton NMR spectrum was obtained, as shown below. Figure 2 As shown. Specific data is as follows: 1H NMR (600 MHz, DMSO) δ: 11.19 (s, 1H), 8.62 (d, J = 6.8 Hz, 1H), 8.08 (s, 1H), 7.79 (s, 4H), 7.29 (d, J = 7.5 Hz, 1H), 6.98 (d, J = 7.7 Hz,1H), 6.89 (t, J = 6,5 Hz, 1H), 6.65 (t, J = 6.5 Hz, 1H), 6.28 (dd, J = 17.0Hz, 10.9 Hz, 1H), 5.23-5.16 (m, 2H), 4.95 (s, 1H), 4.54-4.48 (m, 1H), 3.76-3.71 (m, 2H), 3.69 (s, 3H), 1.62 (s, 6H). 13C NMR (150 MHz, DMSO) δ: 171.0,166.3, 166.3, 163.9, 145.7, 144.8, 134.9, 134.4, 132.1, 131.6, 131.6, 125.1,123.0, 122.9, 120.8, 120.4, 119.3, 118.0, 112.0, 111.7, 105.3, 61.3, 55.6,51.7, 27.7.
[0039] (4) Preparation of the fourth intermediate product The synthetic route for the fourth intermediate is shown in the following formula: .
[0040] The specific synthesis method is as follows: 6g of the third intermediate (4a) was dissolved in isopropanol, followed by the addition of hydrazine hydrate. The mixture was stirred at 25°C for 2 hours to carry out a deprotection reaction. After the deprotection reaction was completed, the reaction mixture was quenched with saturated ammonium chloride solution, and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were then washed with saturated sodium chloride solution, dried with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was dissolved in a mixed solution of ethanol and toluene, and acetic acid was added dropwise. The mixture was stirred at 100°C for 12 hours to carry out a cyclization reaction. After the cyclization reaction was completed, the reaction mixture was quenched with saturated sodium bicarbonate solution, and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were then washed with saturated sodium chloride solution, dried with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain 2.1g of the fourth intermediate (5a). The molar ratio of the third intermediate, hydrazine hydrate, and acetic acid was 1:6:10; the molar ratio of the third intermediate, the volume of isopropanol, the volume of toluene, and the volume of ethanol was 1 mmol:40 mL:40 mL:40 mL.
[0041] (5) Preparation of Neoechinulin B The synthetic route for Neoechinulin B is shown below: .
[0042] The specific synthesis method is as follows: 2.1 g of the fourth intermediate (5a), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, and cuprous chloride were dissolved in dichloromethane and stirred at 25 °C for 15 h to carry out a cyclization and dehydration reaction. After the reaction was completed, the reaction mixture was quenched with saturated sodium chloride solution, and the aqueous layer was extracted three times with dichloromethane. The combined organic layers were then washed with saturated sodium chloride solution, dried with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. 1.54 g of Neoechinulin B was obtained by recrystallization and purification. The molar ratio of the fourth intermediate, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, and cuprous chloride was 1:1.75:0.01; the molar ratio of the fourth intermediate to the volume of dichloromethane was 1 mmol:40 mL.
[0043] The yield of Neoechinulin B, calculated from the third intermediate, was 40%.
[0044] Neoechinulin B was characterized by nuclear magnetic resonance (NMR), and the proton NMR spectrum of Neoechinulin B was obtained, as shown below. Figure 3 As shown. Specific data is as follows: 1 H NMR (600 MHz, CDCl3) δ: 8.80 (s, 1H), 8.35 (s, 1H), 7.67(s, 1H), 7.37 (d, J = 7.9 Hz, 1H), 7.32 (d, J = 5.9 Hz, 7.28 (s, 1H), 13C NMR (150) MHz, CDCl3) δ: 157.8,156.0, 144.5, 144.4, 134.6, 133.8, 126.1, 124.7, 122.7, 121.5, 119.2, 113.6, 113.3, 111.5, 103.3, 102.2, 39.4, 27.6, 1.2.
[0045] Therefore, this invention uses tryptophan ester hydrochloride as the starting material and proceeds sequentially through acylation, isopentenylation, oxidative dehydrogenation, hydrolysis, amino acid condensation, deprotection, cyclization, and cyclization-dehydration reactions to obtain Neoechinulin B. This method utilizes readily available raw materials, has a relatively simple synthetic route, relatively mild reaction conditions, and is easy to purify. It can achieve gram-scale preparation of Neoechinulin B, providing a material basis for its subsequent pharmacological activity research and drug development, and has broad application prospects.
[0046] Finally, it should be noted that the above embodiments are merely illustrative examples for clear explanation and are not intended to limit the implementation. Those skilled in the art will recognize that other variations or modifications can be made based on the above description. It is neither necessary nor possible to exhaustively list all possible implementations here. However, obvious variations or modifications derived therefrom are still within the scope of protection of this invention.
Claims
1. A gram-scale preparation method for Neoechinulin B, characterized in that, Includes the following steps: S1. Tryptophan ester hydrochloride is acylated with phthalic anhydride, and then isopentenyl-9-BBN is added to carry out isopentenylation to obtain the first intermediate product. S2. The first intermediate product is subjected to an oxidative dehydrogenation reaction with 2,3-dichloro-5,6-dicyanobenzoquinone to obtain the second intermediate product; S3. After hydrolyzing the second intermediate with lithium chloride, serine methyl ester hydrochloride, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and 1-hydroxybenzotriazole are added to carry out an amino acid condensation reaction to obtain the third intermediate. S4. The third intermediate product is deprotected with hydrazine hydrate, and then acetic acid is added to carry out a cyclization reaction to obtain the fourth intermediate product. S5. The fourth intermediate, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, was subjected to a cyclization and dehydration reaction with cuprous chloride to obtain Neoechinulin B.
2. The preparation method according to claim 1, characterized in that, In S1, the specific steps of the acylation reaction include: dissolving tryptophan ester hydrochloride, phthalic anhydride and triethylamine in toluene, and refluxing and stirring at 80-150℃ for 9-25h to obtain an acylation intermediate; tryptophan ester hydrochloride is selected from at least one of D-tryptophan methyl ester hydrochloride and L-tryptophan methyl ester hydrochloride.
3. The preparation method according to claim 1, characterized in that, In S1, the specific steps of the isopentenylation reaction include: under the protection of an inert gas, dissolving the acylation intermediate and triethylamine in tetrahydrofuran, then adding tert-butyl hypochlorite, followed by dropwise addition of a tetrahydrofuran solution containing isopentenyl-9-BBN; the temperature of the isopentenylation reaction is -78 to 45°C, and the time is 2 to 7 hours; the molar ratio of tryptophan ester hydrochloride, phthalic anhydride, triethylamine, tert-butyl hypochlorite and isopentenyl-9-BBN is 1:(0.5-3.5):(1-5):(1-3.5):(1-6); the ratio of the amount of tryptophan ester hydrochloride, the volume of toluene and the volume of tetrahydrofuran is 1 mmol:(1-40) mL:(1-40) mL; the inert gas is selected from at least one of nitrogen and argon.
4. The preparation method according to claim 1, characterized in that, In S2, the specific steps of the oxidative dehydrogenation reaction include: dissolving the first intermediate product and 2,3-dichloro-5,6-dicyanobenzoquinone in toluene and stirring at 70-120℃ for 2-6 h; the molar ratio of the first intermediate product to 2,3-dichloro-5,6-dicyanobenzoquinone is 1:(1-7); the molar ratio of the first intermediate product to the volume of toluene is 1 mmol:(3-80) mL.
5. The preparation method according to claim 1, characterized in that, In S3, the specific steps of the hydrolysis reaction include: dissolving the second intermediate product and lithium chloride in N,N-dimethylformamide, stirring at 120-200℃ for 2-15 h to obtain the hydrolysis product; the specific steps of the amino acid condensation reaction include: mixing and stirring the hydrolysis product with an acetonitrile solution containing serine methyl ester hydrochloride, followed by adding 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, 1-hydroxybenzotriazole and N,N-dimethylformamide; the temperature of the amino acid condensation reaction is 0-40℃, and the time is 12-24 h.
6. The preparation method according to claim 1, characterized in that, In S3, the molar ratio of the second intermediate, lithium chloride, serine methyl ester hydrochloride, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, and 1-hydroxybenzotriazole is 1:(1-20):(1-5):(1-3):(1-3); the molar ratio of the second intermediate, the volume of N,N-dimethylformamide, and the volume of acetonitrile is 1 mmol:(0.5-70) mL:(3-70) mL; the serine methyl ester hydrochloride is selected from at least one of D-serine methyl ester hydrochloride and L-serine methyl ester hydrochloride.
7. The preparation method according to claim 1, characterized in that, In S4, the specific steps of the deprotection reaction include: dissolving the third intermediate in isopropanol, then adding hydrazine hydrate, and stirring at 0-40℃ for 1-3 h to obtain the crude product; the specific steps of the cyclization reaction include: dissolving the crude product in a mixed solution of ethanol and toluene, adding acetic acid dropwise, and stirring at 80-150℃ for 3-12 h.
8. The preparation method according to claim 1, characterized in that, In S4, the molar ratio of the third intermediate, hydrazine hydrate, and acetic acid is 1:(1-10):(5-15); the ratio of the amount of the third intermediate, the volume of isopropanol, the volume of toluene, and the volume of ethanol is 1 mmol:(4-50) mL:(4-50) mL:(4-50) mL.
9. The preparation method according to claim 1, characterized in that, In S5, the specific steps of the cyclization dehydration reaction include: dissolving the fourth intermediate, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and cuprous chloride in dichloromethane and stirring at 0-40℃ for 5-24h; the molar ratio of the fourth intermediate, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride and cuprous chloride is 1:(0.5-3):(0.01-1); the molar ratio of the fourth intermediate to the volume of dichloromethane is 1 mmol:(4-50) mL.
10. A Neoechinulin B, characterized in that, Neoechinulin B was prepared by the gram-scale preparation method according to any one of claims 1-9.
